Telix Elects to Withdraw from Proposed U.S. Listing
Telix today announces that it has elected to withdraw its proposed initial public offering (IPO) in the United…
Read moreNews & Views
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET…
Read more
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic…
Read more
Telix Highlights ProstACT GLOBAL and STARLITE-1 Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2024
News,
Telix today announces two abstract presentations featuring the Company’s therapeutic radiopharmaceutical programs at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from…
Read more
Telix Submits NDA for New Prostate Cancer Imaging Agent
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”)…
Read more
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Telix today announces the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate…
Read more
Telix Announces Abstract Presentations at BNMS Annual Spring Meeting
Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week….
Read more
Telix and Cardinal Health Complete Global Clinical Supply Agreement for Actinium-225 for Targeted Alpha Therapy Pipeline Development
News,
Telix today announces an agreement with Cardinal Health Nuclear & Precision Health Solutions (a subsidiary of Cardinal Health, Inc.) for the global clinical supply of actinium-225 (Ac-225), a therapeutic radioisotope…
Read more
Telix Completes Acquisition of QSAM Biosciences and Its Bone Cancer Targeting Platform
Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company…
Read more
First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX…
Read more